BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
News | 03. 04. 2025
Tune Therapeutics
DURHAM, N.C. & SEATTLE--March 4, 2025--Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, MD will be its new CEO and Chairman of the Board. Dr. McHutchison is an internationally recognized leader of the biopharma industry and accomplished drug developer who brings decades of executive leadership and experience in developing novel therapeutics.
